NCT02134951View on ClinicalTrials.gov

Biomarker Assessment of Glutamatergic Target Engagement

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy Controls
Interventions
DRUG

Ketamine

intravenous infusion of saline solution with ketamine

DRUG

Normal saline

Normal saline will be used for placebo in this group

Trial Locations (3)

10032

New York State Psychiatric Institute, New York

95817

University of California Davis, Sacramento

06511

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02134951 - Biomarker Assessment of Glutamatergic Target Engagement | Biotech Hunter | Biotech Hunter